Form 6-K Rosetta Genomics Ltd. For: Dec 01
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Rosetta Genomics (ROSG) Reports Q3 EPS of $0.27
December 1, 2015 7:55 AM ESTRosetta Genomics (NASDAQ: ROSG) reported Q3 EPS of $0.27, versus $0.29 reported last year. Revenue for the quarter came in at $2.43 million, versus $273 thousand reported last year.
Management Commentary
During recent months we continued to make meaningful progress integrating the PersonalizeDx acquisition, growing top-line results, expanding our high-value molecular diagnostics offerings with important product launches, upgrading our sales and reimbursement infrastructure and strengthening our balance sheet, stated Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics.
The third quarter of 2015 was the first full quarter of PersonalizeDx... More
